Transdermal Drug Delivery Systems Market Size to Hit USD 239.43 Billion by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Transdermal Drug Delivery Systems Market

5.1. COVID-19 Landscape: Transdermal Drug Delivery Systems Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Transdermal Drug Delivery Systems Market, By System Technology

8.1. Transdermal Drug Delivery Systems Market, by System Technology

8.1.1. Drug in adhesive patches

8.1.1.1. Market Revenue and Forecast

8.1.2. Matrix patches

8.1.2.1. Market Revenue and Forecast

8.1.3. Reservoir patches

8.1.3.1. Market Revenue and Forecast

8.1.4. Microreservoir patches

8.1.4.1. Market Revenue and Forecast

8.1.5. Microneedle transdermal systems

8.1.5.1. Market Revenue and Forecast

Chapter 9. Global Transdermal Drug Delivery Systems Market, By Therapeutic Area

9.1. Transdermal Drug Delivery Systems Market, by Therapeutic Area

9.1.1. Pain management

9.1.1.1. Market Revenue and Forecast

9.1.2. Hormone replacement therapy

9.1.2.1. Market Revenue and Forecast

9.1.3. Contraception

9.1.3.1. Market Revenue and Forecast

9.1.4. Neurological and CNS disorders

9.1.4.1. Market Revenue and Forecast

9.1.5. Cardiovascular therapy

9.1.5.1. Market Revenue and Forecast

9.1.6. Smoking cessation

9.1.6.1. Market Revenue and Forecast

Chapter 10. Global Transdermal Drug Delivery Systems Market, By End User

10.1. Transdermal Drug Delivery Systems Market, by End User

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast

10.1.2. Specialty clinics

10.1.2.1. Market Revenue and Forecast

10.1.3. Homecare

10.1.3.1. Market Revenue and Forecast

Chapter 11. Global Transdermal Drug Delivery Systems Market, By Distribution Channel

11.1. Transdermal Drug Delivery Systems Market, by Distribution Channel

11.1.1. Hospital pharmacies

11.1.1.1. Market Revenue and Forecast

11.1.2. Retail pharmacies

11.1.2.1. Market Revenue and Forecast

11.1.3. Online pharmacies

11.1.3.1. Market Revenue and Forecast

11.1.4. Direct institutional procurement

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global Transdermal Drug Delivery Systems Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by System Technology

12.1.2. Market Revenue and Forecast, by Therapeutic Area

12.1.3. Market Revenue and Forecast, by End User

12.1.4. Market Revenue and Forecast, by Distribution Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by System Technology

12.1.5.2. Market Revenue and Forecast, by Therapeutic Area

12.1.5.3. Market Revenue and Forecast, by End User

12.1.5.4. Market Revenue and Forecast, by Distribution Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by System Technology

12.1.6.2. Market Revenue and Forecast, by Therapeutic Area

12.1.6.3. Market Revenue and Forecast, by End User

12.1.6.4. Market Revenue and Forecast, by Distribution Channel

12.2. Europe

12.2.1. Market Revenue and Forecast, by System Technology

12.2.2. Market Revenue and Forecast, by Therapeutic Area

12.2.3. Market Revenue and Forecast, by End User

12.2.4. Market Revenue and Forecast, by Distribution Channel

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by System Technology

12.2.5.2. Market Revenue and Forecast, by Therapeutic Area

12.2.5.3. Market Revenue and Forecast, by End User

12.2.5.4. Market Revenue and Forecast, by Distribution Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by System Technology

12.2.6.2. Market Revenue and Forecast, by Therapeutic Area

12.2.6.3. Market Revenue and Forecast, by End User

12.2.6.4. Market Revenue and Forecast, by Distribution Channel

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by System Technology

12.2.7.2. Market Revenue and Forecast, by Therapeutic Area

12.2.7.3. Market Revenue and Forecast, by End User

12.2.7.4. Market Revenue and Forecast, by Distribution Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by System Technology

12.2.8.2. Market Revenue and Forecast, by Therapeutic Area

12.2.8.3. Market Revenue and Forecast, by End User

12.2.8.4. Market Revenue and Forecast, by Distribution Channel

12.3. APAC

12.3.1. Market Revenue and Forecast, by System Technology

12.3.2. Market Revenue and Forecast, by Therapeutic Area

12.3.3. Market Revenue and Forecast, by End User

12.3.4. Market Revenue and Forecast, by Distribution Channel

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by System Technology

12.3.5.2. Market Revenue and Forecast, by Therapeutic Area

12.3.5.3. Market Revenue and Forecast, by End User

12.3.5.4. Market Revenue and Forecast, by Distribution Channel

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by System Technology

12.3.6.2. Market Revenue and Forecast, by Therapeutic Area

12.3.6.3. Market Revenue and Forecast, by End User

12.3.6.4. Market Revenue and Forecast, by Distribution Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by System Technology

12.3.7.2. Market Revenue and Forecast, by Therapeutic Area

12.3.7.3. Market Revenue and Forecast, by End User

12.3.7.4. Market Revenue and Forecast, by Distribution Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by System Technology

12.3.8.2. Market Revenue and Forecast, by Therapeutic Area

12.3.8.3. Market Revenue and Forecast, by End User

12.3.8.4. Market Revenue and Forecast, by Distribution Channel

12.4. MEA

12.4.1. Market Revenue and Forecast, by System Technology

12.4.2. Market Revenue and Forecast, by Therapeutic Area

12.4.3. Market Revenue and Forecast, by End User

12.4.4. Market Revenue and Forecast, by Distribution Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by System Technology

12.4.5.2. Market Revenue and Forecast, by Therapeutic Area

12.4.5.3. Market Revenue and Forecast, by End User

12.4.5.4. Market Revenue and Forecast, by Distribution Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by System Technology

12.4.6.2. Market Revenue and Forecast, by Therapeutic Area

12.4.6.3. Market Revenue and Forecast, by End User

12.4.6.4. Market Revenue and Forecast, by Distribution Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by System Technology

12.4.7.2. Market Revenue and Forecast, by Therapeutic Area

12.4.7.3. Market Revenue and Forecast, by End User

12.4.7.4. Market Revenue and Forecast, by Distribution Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by System Technology

12.4.8.2. Market Revenue and Forecast, by Therapeutic Area

12.4.8.3. Market Revenue and Forecast, by End User

12.4.8.4. Market Revenue and Forecast, by Distribution Channel

12.5. Latin America

12.5.1. Market Revenue and Forecast, by System Technology

12.5.2. Market Revenue and Forecast, by Therapeutic Area

12.5.3. Market Revenue and Forecast, by End User

12.5.4. Market Revenue and Forecast, by Distribution Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by System Technology

12.5.5.2. Market Revenue and Forecast, by Therapeutic Area

12.5.5.3. Market Revenue and Forecast, by End User

12.5.5.4. Market Revenue and Forecast, by Distribution Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by System Technology

12.5.6.2. Market Revenue and Forecast, by Therapeutic Area

12.5.6.3. Market Revenue and Forecast, by End User

12.5.6.4. Market Revenue and Forecast, by Distribution Channel

Chapter 13. Company Profiles

13.1. Teva Pharmaceutical Industries

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Hisamitsu Pharmaceutical

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Viatris

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Novartis

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Johnson & Johnson

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Bayer

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. UCB

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Zydus Lifesciences

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. 3M

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Nitto Denko

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The transdermal drug delivery systems market size is expected to increase from USD 78.20 billion in 2025 to USD 239.43 billion by 2035.

Answer : The transdermal drug delivery systems market is expected to grow at a compound annual growth rate (CAGR) of around 11.84% from 2026 to 2035.

Answer : The major players in the transdermal drug delivery systems market include Teva Pharmaceutical Industries, Hisamitsu Pharmaceutical, Viatris, Novartis, Johnson & Johnson, Bayer, UCB, Zydus Lifesciences, 3M, Nitto Denko, LTS Lohmann Therapie-Systeme, Corium, Luye Pharma Group, Teikoku Pharma USA, and Kindeva Drug Delivery.

Answer : The driving factors of the transdermal drug delivery systems market are the improved patient compliance with non-invasive and painless gels and patches, and innovations in drug-delivery technologies are expanding the adoption of transdermal drug delivery systems.

Answer : North America region will lead the global transdermal drug delivery systems market during the forecast period 2026 to 2035.